NEW YORK (GenomeWeb) – CLIA certified laboratory CompanionDx has tapped N-of-One to provide clinical interpretation services for its targeted next generation sequencing-based tests.
Under the terms of the agreement announced today, N-of-One will interpret data from CompanionDx's focused and comprehensive oncology panels. CompanionDx offers next-generation sequencing and pharmacogenomics testing that identifies key changes or somatic mutations in patient samples and provides insights into patients' potential for metabolizing particular drugs. N-of-One's interpretation services provide scientific and clinical evidence in support of possible therapeutic strategies relevant to each specific patient case. That includes insights into the implication of each patient’s molecular profile on drug sensitivity, drug resistance, and potential combination therapies.
Patient-specific results and cost-effectiveness of the interpretation services were the reasons CompanionDx selected N-of-One as its partner, Michael Stewart, CompanionDx's CEO said in a statement. "N-of-One clinical interpretation will help us deliver high-quality results for our focused NGS panels as well as our larger comprehensive panels."
Financial and other terms of the agreement were not disclosed.